Madrigal Pharmaceuticals (NASDAQ:MDGL) Lifted to Sell at StockNews.com

StockNews.com upgraded shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) to a sell rating in a report released on Tuesday morning. Other research analysts have also recently issued research reports about the stock. JMP Securities restated a market outperform rating and set a $383.00 price objective on shares of Madrigal Pharmaceuticals in a report on […]

Leave a Reply

Your email address will not be published.

Previous post OPKO Health (NASDAQ:OPK) Upgraded to “Hold” by StockNews.com
Next post Mastercard (NYSE:MA) Stock Rating Reaffirmed by BMO Capital Markets